These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 36273937)

  • 1. FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.
    Shi MJ; Fontugne J; Moreno-Vega A; Meng XY; Groeneveld C; Dufour F; Kamoun A; Viborg Lindskrog S; Cabel L; Krucker C; Rapinat A; Dunois-Larde C; Lepage ML; Chapeaublanc E; Levrel O; Dixon V; Lebret T; Almeida A; De Reynies A; Rochel N; Dyrskjøt L; Allory Y; Radvanyi F; Bernard-Pierrot I
    Eur Urol; 2023 Jan; 83(1):70-81. PubMed ID: 36273937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation.
    Foth M; Ismail NFB; Kung JSC; Tomlinson D; Knowles MA; Eriksson P; Sjödahl G; Salmond JM; Sansom OJ; Iwata T
    J Pathol; 2018 Nov; 246(3):331-343. PubMed ID: 30043421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors.
    Groeneveld CS; Sanchez-Quiles V; Dufour F; Shi M; Dingli F; Nicolle R; Chapeaublanc E; Poullet P; Jeffery D; Krucker C; Maillé P; Vacherot F; Vordos D; Benhamou S; Lebret T; Micheau O; Zinovyev A; Loew D; Allory Y; de Reyniès A; Bernard-Pierrot I; Radvanyi F
    Eur Urol; 2024 May; 85(5):483-494. PubMed ID: 37380559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of FGFR3 mutations in urinary bladder tumours of rats and mice treated with N-butyl-N-(-4-hydroxybutyl)nitrosamine.
    Dunois-Lardé C; Levrel O; Brams A; Thiery JP; Radvanyi F
    Mol Carcinog; 2005 Mar; 42(3):142-9. PubMed ID: 15690367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.
    Tomlinson DC; Hurst CD; Knowles MA
    Oncogene; 2007 Aug; 26(40):5889-99. PubMed ID: 17384684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor.
    Hsu JW; Hsu I; Xu D; Miyamoto H; Liang L; Wu XR; Shyr CR; Chang C
    Am J Pathol; 2013 May; 182(5):1811-20. PubMed ID: 23499463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR3b Extracellular Loop Mutation Lacks Tumorigenicity In Vivo but Collaborates with p53/pRB Deficiency to Induce High-grade Papillary Urothelial Carcinoma.
    Zhou H; He F; Mendelsohn CL; Tang MS; Huang C; Wu XR
    Sci Rep; 2016 May; 6():25596. PubMed ID: 27157475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.
    di Martino E; L'Hôte CG; Kennedy W; Tomlinson DC; Knowles MA
    Oncogene; 2009 Dec; 28(48):4306-16. PubMed ID: 19749790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
    Otto W; Denzinger S; Bertz S; Gaumann A; Wild PJ; Hartmann A; Stoehr R
    Int J Cancer; 2009 Nov; 125(9):2205-8. PubMed ID: 19621447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder.
    Cheng L; Lopez-Beltran A; Wang M; Whaley RD; De Souza A; Au S; Ge R; Cimadamore A; Amin A; Golijanin B; MacLennan GT; Osunkoya AO; Montironi R; Zhang S
    Mod Pathol; 2023 Jul; 36(7):100151. PubMed ID: 36906071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice.
    Foth M; Ahmad I; van Rhijn BW; van der Kwast T; Bergman AM; King L; Ridgway R; Leung HY; Fraser S; Sansom OJ; Iwata T
    J Pathol; 2014 Jun; 233(2):148-58. PubMed ID: 24519156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditional Expression of the Androgen Receptor Increases Susceptibility of Bladder Cancer in Mice.
    Johnson DT; Hooker E; Luong R; Yu EJ; He Y; Gonzalgo ML; Sun Z
    PLoS One; 2016; 11(2):e0148851. PubMed ID: 26862755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Artificial Intelligence-based Detection of FGFR3 Mutational Status Directly from Routine Histology in Bladder Cancer: A Possible Preselection for Molecular Testing?
    Loeffler CML; Ortiz Bruechle N; Jung M; Seillier L; Rose M; Laleh NG; Knuechel R; Brinker TJ; Trautwein C; Gaisa NT; Kather JN
    Eur Urol Focus; 2022 Mar; 8(2):472-479. PubMed ID: 33895087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.
    Shi MJ; Meng XY; Lamy P; Banday AR; Yang J; Moreno-Vega A; Chen CL; Dyrskjøt L; Bernard-Pierrot I; Prokunina-Olsson L; Radvanyi F
    Eur Urol; 2019 Jul; 76(1):9-13. PubMed ID: 30975452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular investigation of FGFR3 gene mutation and its correlation with clinicopathological findings in Indian bladder cancer patients.
    Ahmad F; Mahal V; Verma G; Bhatia S; Das BR
    Cancer Rep (Hoboken); 2018 Oct; 1(3):e1130. PubMed ID: 32721083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.
    Dodurga Y; Tataroglu C; Kesen Z; Satiroglu-Tufan NL
    Genet Mol Res; 2011 Jan; 10(1):86-95. PubMed ID: 21264819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
    Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
    Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?
    van Rhijn BWG; Mertens LS; Mayr R; Bostrom PJ; Real FX; Zwarthoff EC; Boormans JL; Abas C; van Leenders GJLH; Götz S; Hippe K; Bertz S; Neuzillet Y; Sanders J; Broeks A; van der Heijden MS; Jewett MAS; Marquez M; Stoehr R; Zlotta AR; Eckstein M; Soorojebally Y; Roshani H; Burger M; Otto W; Radvanyi F; Sirab N; Pouessel D; Wullich B; van der Kwast TH; Malats N; Hartmann A; Allory Y; Zuiverloon TCM
    Eur Urol; 2020 Nov; 78(5):682-687. PubMed ID: 32682615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.
    Billerey C; Chopin D; Aubriot-Lorton MH; Ricol D; Gil Diez de Medina S; Van Rhijn B; Bralet MP; Lefrere-Belda MA; Lahaye JB; Abbou CC; Bonaventure J; Zafrani ES; van der Kwast T; Thiery JP; Radvanyi F
    Am J Pathol; 2001 Jun; 158(6):1955-9. PubMed ID: 11395371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.